Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 3/20 | 0.31 |
| ▸ | NOS2 | P35228 | 3/20 | 0.31 |
| ▸ | NOS1 | P29475 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29846963 | 1.00 | NOS3 (0.31) | NOS3NOS2NOS1 | |
| SCHEMBL29552440 | 0.78 | TLR7 (0.31) | — | |
| SCHEMBL12389423 | 0.77 | NOS3 (0.33) | NOS3NOS2NOS1 | |
| SCHEMBL28238762 | 0.74 | — | — | |
| SCHEMBL30743598 | 0.74 | NOS3 (0.36) | NOS3NOS2NOS1 | |
| SCHEMBL5925876 | 0.74 | NOS3 (0.36) | NOS3NOS2NOS1 | |
| SCHEMBL22876719 | 0.73 | — | — | |
| SCHEMBL17857743 | 0.72 | NOS3 (0.30) | NOS3NOS2NOS1 | |
| SCHEMBL18625352 | 0.72 | NOS3 (0.30) | NOS3NOS2NOS1 | |
| SCHEMBL21254693 | 0.72 | NOS3 (0.30) | NOS3NOS2NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110194770-B | Peptidyl arginine deiminase inhibitors and uses thereof | 药捷安康(南京)科技股份有限公司 | 2022-08-09 | — | — | CN | disclosed |
| EP-3760628-A1 | PEPTIDYLARGININE DEIMINASE INHIBITOR AND USE THEREOF | Nanjing Transthera Biosciences Co., Ltd. (CN) | 2021-01-06 | — | — | EP | disclosed |
| EP-3760628-A1 | PEPTIDYLARGININE DEIMINASE INHIBITOR AND USE THEREOF | Nanjing Transthera Biosciences Co., Ltd. (CN) | 2021-01-06 | — | — | EP | disclosed |
| US-20200407370-A1 | PEPTIDYLARGININE DEIMINASE INHIBITOR AND USE THEREOF | NANJING TRANSTHERA BIOSCIENCES CO., LTD. (CN) | 2020-12-31 | — | — | US | disclosed |
| US-20200407370-A1 | PEPTIDYLARGININE DEIMINASE INHIBITOR AND USE THEREOF | NANJING TRANSTHERA BIOSCIENCES CO., LTD. (CN) | 2020-12-31 | — | — | US | disclosed |
| WO-2020206583-A1 | KINASE INHIBITORS AND USES THEREOF | QILU REGOR THERAPEUTICS INC. (CN) | 2020-10-15 | — | — | WO | disclosed |
| WO-2019161803-A1 | PEPTIDYLARGININE DEIMINASE INHIBITOR AND USE THEREOF | 南京药捷安康生物科技有限公司 | 2019-08-29 | — | — | WO | disclosed |
| WO-2019161803-A1 | PEPTIDYLARGININE DEIMINASE INHIBITOR AND USE THEREOF | 南京药捷安康生物科技有限公司 | 2019-08-29 | — | — | WO | disclosed |
| EP-3233829-B1 | PYRIMIDINE AND TRIAZINE DERIVATIVES AND THEIR USE AS AXL INHIBITORS | PFIZER (US) | 2019-08-14 | — | — | EP | disclosed |
| EP-3233829-A1 | PYRIMIDINE AND TRIAZINE DERIVATIVES AND THEIR USE AS AXL INHIBITORS | Pfizer Inc (US) | 2017-10-25 | — | — | EP | disclosed |
| US-9593097-B2 | Axl inhibitors | PFIZER INC. (US) | 2017-03-14 | — | — | US | disclosed |
| WO-2016097918-A1 | PYRIMIDINE AND TRIAZINE DERIVATIVES AND THEIR USE AS AXL INHIBITORS | PFIZER INC. (US) | 2016-06-23 | — | — | WO | disclosed |
| US-20160176850-A1 | AXL INHIBITORS | PFIZER INC. | 2016-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200407370-A1 | PEPTIDYLARGININE DEIMINASE INHIBITOR AND USE THEREOF | PADI4, PADI2, PADI1 | NOS3 341/4885NOS2 583/4885NOS1 351/4885 |
| US-20160176850-A1 | AXL INHIBITORS | AXL, FLT3, MERTK | NOS3 2029/4885NOS2 1721/4885NOS1 1536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.